Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791894 | 0.83 | TAAR1 (0.73) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL3241000 | 0.82 | MAPT (0.67) | ALDH1A1MAPTKMT2AMAPK1MEN1 | |
| SCHEMBL9795671 | 0.79 | TAAR1 (0.62) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL6790627 | 0.79 | TAAR1 (0.58) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL3708228 | 0.78 | TAAR1 (0.61) | TAAR1SLC2A1MAPTKMT2AMAPK1 | |
| SCHEMBL17800983 | 0.78 | RHOA (0.45) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL8084560 | 0.77 | TAAR1 (0.59) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL6784490 | 0.77 | TAAR1 (0.59) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL6789185 | 0.76 | TAAR1 (0.62) | TAAR1SLC2A1ALDH1A1MAPTKMT2A | |
| SCHEMBL9017608 | 0.76 | TAAR1 (0.62) | TAAR1SLC2A1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | TAAR1 242/4885SLC2A1 1938/4885ALDH1A1 1921/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | TAAR1 75/4885SLC2A1 1449/4885ALDH1A1 1194/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | TAAR1 270/4885SLC2A1 1700/4885ALDH1A1 2098/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | TAAR1 464/4885SLC2A1 1808/4885ALDH1A1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.